Conclusions. Continuous use of MMF versus AZA was associated with a protective effect against declining renal function beyond 1 year after transplantation. Further study is needed to confirm that continued MMF therapy is protective against long-term deterioration in renal function.
As graft and patient survival have improved, renal transplantation has become an effective treatment for end-stage renal disease (1) . However, with the increased treatment successes and improvements in patient management, differences in long-term outcomes have become more difficult to measure. Establishing relevant indicators for long-term graft outcomes is important for the future development and assessment of new treatment options.
Recent studies indicate that renal function may be an early indicator of outcomes after renal transplantation. However, many of these studies have focused primarily on serum creatinine (SCr) in the first year after transplantation. SCr levels at 10 days (2), 6 months (3, 4) , and 1 year (5, 6) posttransplantation have been correlated with long-term graft survival. Few studies, however, have investigated measures of chronic change in renal allograft function. A recent report compared the predictive value of early and late measures of renal function and found that late changes in 1/SCr show the strongest association with long-term graft survival (7) .
Because poor renal function at 1-year posttransplantation has been shown to strongly correlate with the risk for patient death, graft survival, and cardiovascular death independent of graft loss (8) , it was important to investigate late changes in renal function as an overall indicator of long-term outcomes. In addition to the absolute measure of renal function, patients who have worsening renal function might be at particular risk for graft loss. For this reason, we compared the slope of reciprocal SCr in patients on long-term (minimum of 1 year) mycophenolate mofetil (MMF) therapy with patients on azathioprine (AZA).
Current prospective and retrospective studies have focused on the benefits of MMF versus AZA therapy in an intent-totreat fashion on the basis of the medication the patients were started on only at the beginning of the study. However, the benefits of long-term therapy are not well understood. To investigate the hypothesis that long-term treatment (1 and 2 years) with MMF is associated with a statistically significant reduced risk of renal function decline, data were analyzed from primary renal allograft recipients reported to the United States Renal Data System (USRDS) database. Patients who remained on either MMF or AZA were studied in an intent-to-treat analysis for (1) a minimum period of 12 months after transplantation (9,096 on MMF; 40,570 on AZA) or (2) a minimum of 24 months after transplantation (2,762 on MMF; 31,631 on AZA). The treatment course was determined by examining reported medications at discharge and subsequent follow-up visits, as recorded on the USRDS case forms. Treatment groups were defined by the immunosuppressive medication at the time of discharge (MMF vs. AZA), which was recorded for all patients studied, and was an attempt to emulate an intent-to-treat analysis. Maintenance therapy was recorded at follow-up visits (6, 12 , and 24 months). For the purpose of this study, a patient was considered to be on continuous MMF (or AZA) therapy for the entire 12 months after transplantation if the patient was recorded as being on MMF (or AZA) at discharge, 6 months, 12 months, or for the entire 24 months after transplantation (discharge, 6, 12, and 24 months maintenance therapy).
Patients were excluded that met the following clinical criteria: multiorgan transplants (7,972 excluded), pediatric patients aged younger than 18 years (3,755 excluded), drug switching or drug discontinuation during the 12-month prestudy period as determined by a different recorded medication at any of the follow-up visits (9,264 excluded), and patients with both MMF and AZA recorded as maintenance therapy in the same time period (955 excluded).
The primary endpoint of the study was defined as a greater than 20% decrease below a 6-month baseline of 1/SCr (slope of reciprocal SCr) at or beyond 1 year after transplantation. The slope of reciprocal SCr was chosen because it reflects a linear association with the degree of renal allograft impairment, whereas the change in the unadjusted SCr is not a linear function. A combined endpoint of slope of reciprocal SCr, graft loss, or patient death, whichever event occurred first, was used.
SCr values were obtained at follow-up visits, as recorded on the United Network for Organ Sharing kidney transplant recipient fol- A secondary endpoint was defined as reaching an SCr value of 1.6 mg/dL or higher beyond 12 months after transplantation. This endpoint was also investigated as the combined endpoint of SCr, graft loss, and patient death. Univariate Kaplan-Meier analysis was used to compare the MMF and AZA treatment groups by evaluating the fraction of patients who experienced declining renal function, as measured by the slope of reciprocal creatinine (20% change) and by reaching an SCr value greater than 1.6 mg/dL at or beyond 1 year posttransplantation. P values were calculated and log-rank tests performed to determine statistical significance between the two groups.
Cox proportional hazard models were used to investigate the independent effect of MMF on renal allograft function while controlling for relevant risk factors and to investigate the potential differences in mortality rate between the two populations studied. The multivariate analyses were corrected for 12 potential confounding covariates including the following: year of transplant, donor and recipient demographics, degree of human leukocyte antigen matching, cytomegalovirus status, living versus cadaveric donor, acute rejection (before 6 months posttransplantation), time on dialysis, and type of calcineurin inhibitor (CNI) used. In the multivariate analysis, distinct CNIs at discharge were corrected for, including cyclosporine (CsA) microemulsion, conventional CsA formulation, and tacrolimus. Mean values were used for missing data, including donor age (399 patients), years of dialysis (115 patients), and cold ischemia time (3,284 patients). Univariate proportionality checks were performed for all Cox models. A probability of type 1 error ␣ϭ0.05 was considered the threshold of statistical significance. For multiple comparisons, the threshold of statistical significance was adjusted by the Bonferroni correction in which a probability of type 1 error (␣Ͻ0.017) was considered to be the threshold of statistical significance for this analysis. The statistical analyses were performed with SAS version 8.2 (Windows NT version; SAS Institute, Cary, NC). Table 1 shows the baseline study population characteristics for the AZA and MMF treatment groups. Worsening renal function, as defined by the reciprocal slope of creatinine, occurred for 14.4% of the study population during the first study year (7,160/49,666), 14.0% during the second study year (5,177/37,090), and 12.4% during the third study year (3,521/28,404).
RESULTS
Kaplan-Meier analysis for the slope of reciprocal SCr by maintenance group, MMF versus AZA, in the combined endpoint analysis (Fig. 1) showed a significantly lower incidence of worsening renal function at 3 and 4 years posttransplantation in the MMF group (22.7% at 3 years and 29.6% at 4 years) compared with the AZA-treated group (27.7% at 3 years and 36.6% at 4 years). Results were similar in the analysis in which death and graft loss were censored (Fig. 2) in the MMF group (15.8% at 3 years and 19.2% at 4 years) compared with the AZA-treated group (22.1% at 3 years and 29.5% at 4 years).
The Cox proportional hazard model (Table 2) demonstrates that MMF therapy was associated with a 16% risk reduction (relative risk [RR]ϭ0.84, PϽ0.001) for worsening renal function compared with AZA therapy. Throughout the study period, a living donor (RRϭ0.86, PϽ0.001) was also noted to be associated with a decreased risk of deteriorating renal function. Significant risk factors for worsening renal function beyond 12 months after transplantation included older donor age (RRϭ1.48, PϽ0.001), African American recipient race (RRϭ1.45, PϽ0.001), an episode of acute rejection within the first 6 months after transplantation (RRϭ1.17, PϽ0.001), and extended time on dialysis preceding transplantation (RRϭ1.02/year, PϽ0.001). For patients who had been on either MMF or AZA for at least 2 continuous years, MMF was associated with a 34% reduction (RRϭ0.66, PϽ0.001) in the risk of developing worsening renal function beyond 24 months posttransplantation. Substitutions of mean values for missing data were made for a small percentage of patients, and for a small number of covariates, and did not affect the conclusions.
For the secondary endpoint of reaching an SCr threshold of 1.6 mg/dL beyond 12 months after transplantation (combined endpoint), the Kaplan-Meier analysis for worsening renal function in the MMF versus AZA maintenance group showed a significantly lower incidence of worsening renal function at 3 and 4 years posttransplantation in the MMF group (23.6% at 3 years and 31.9% at 4 years) compared with the AZA group (32.4% at 3 years and 40.0% at 4 years) (Fig. 3) . Results were similar for the analysis in which death and graft loss were censored in the MMF group (16.6% at 3 years and 19.5% at 4 years) compared with the AZA-treated group (26.7% at 3 years and 33.8% at 4 years) (Fig. 4) . The Cox proportional hazard model (Table 2) shows that MMF ther- apy was associated with a 20% risk reduction (RRϭ0.80, PϽ0.001) for worsening renal function compared with AZA therapy. Another significant protective factor was having a living donor versus a cadaveric donor (RRϭ0.90, PϽ0.001). Significant risk factors for worsening renal function beyond 12 months after transplantation included older donor age (RRϭ2.18, PϽ0.001), African American recipient race (RRϭ1.48, PϽ0.001), an episode of acute rejection within the first year after transplantation (RRϭ1.23, PϽ0.001), and time on dialysis before transplantation (RRϭ1.01 per year,
PϽ0.001).
Overall patient and graft survival were not significantly worse in the MMF group during the first year. A Cox proportional hazard analysis showed no significant difference in mortality rate between the two drugs for the population studied (RRϭ0.966, Pϭ0.6938). The impact of excluding patients because of switched immunosuppressive therapy after the 12-month prestudy period did not result in a lower-risk population at 1 year in the MMF group. Most of the drug switching occurred from AZA to MMF (nϭ2641), as opposed to MMF to AZA switching (nϭ167).
DISCUSSION
Many new-generation immunosuppressants have been shown to significantly reduce the incidence of acute rejection in the first 6 months after transplantation. However, the long-term benefits of these newer agents have been more difficult to demonstrate, in part because the incidence of study endpoints has been diminishing in recent years (9) . Recent studies indicate that renal function may be an early indicator of outcomes after renal transplantation (1) (2) (3) (4) (5) . Renal dysfunction can indicate clinical situations in which immunosuppression regimens may need to be tailored to maximize graft function and survival, and situations in which causes of comorbidities should be more tightly monitored and managed, notably the high risk of cardiovascular deaths.
This study is the first to demonstrate an association of long-term MMF therapy with improved renal function and a decrease in the risk and incidence of renal function deterioration. Long-term (minimum 1 year) MMF therapy versus AZA was associated with a decreased incidence of worsening renal function, as measured by a 20% decrease below a 6-month baseline of reciprocal creatinine. The 6-month measurement was chosen as the baseline value to reduce the influence of early renal dysfunction (including delayed graft function and acute rejection) on creatinine values. In addition, MMF was associated with a protective effect against experiencing worsening renal function beyond 1 year posttransplantation, as measured by an SCr value greater than 1.6 mg/dL. This endpoint was studied because it has been noted as a risk factor for developing chronic allograft nephropathy. The threshold value of 1.6 mg/dL was selected because it was the cutoff that was published in a study linking SCr thresholds and late graft loss (2, 3) . By studying the combined endpoint (worsening renal function, graft loss, or death), this study ensured that there was no bias by excluding patients who may have experienced the worst outcome of poor graft function, death, or graft loss. In both censored and combined endpoint studies, and in the 12-and 24-month treatment analyses, the results were consistent.
Two recent clinical studies have demonstrated the benefit of adding MMF to the immunosuppressive regimen in patients with worsening renal function who were started on CsA, AZA, and steroids. In patients with biopsy-proven chronic allograft nephropathy, adding MMF and reducing CsA by 50% resulted in the stabilization of renal function without increasing the risk of acute allograft rejection. In this study, the stabilization of renal function could not be solely attributed to either CsA reduction or the addition of MMF (10) . Subsequent studies by this group have shown that complete CsA withdrawal is possible in certain patients with minimal risk of acute rejection (11) . In a recent clinical study, MMF has been shown to slow deteriorating renal function in patients (12) . In this large, multicenter trial, patients with worsening renal function were randomized to treatment with MMF and reduction in CsA or to continued treatment with CsA. In the MMF group, renal function stabilized or improved in 58% of the patients (defined by a flat or positive slope of the reciprocal creatinine plot) compared with 28% in the CsA group. In animal studies of chronic CNI toxicity, MMF treatment after CsA withdrawal has been shown to improve renal function and histologic features of chronic CNI nephropathy (13) .
Other independent risk factors for worsening renal function include African American recipient race, prior episodes of acute rejection, recipient of kidneys from older donors, and time on dialysis preceding transplantation. Each factor has been demonstrated to be a risk factor for graft loss in previous studies and is confirmed in our study for renal function deterioration.
In this study, the requirement for continued therapy with MMF versus AZA for at least 1 year posttransplantation was established to evaluate the effect of long-term treatment on the study endpoints. However, using data from the USRDS registry, we could not continuously monitor therapy. For purposes of this study, therefore, it was assumed that a patient was on a therapy continuously if he was on that therapy at discharge, 6 months, and 1 year posttransplantation, as reported on USRDS follow-up records. For patients who have been on a particular immunosuppression therapy for 12 months, it was assumed that most would continue that therapy for subsequent periods. Because no data about drug doses are available from the USRDS database, this study could not ascertain which dose would be the minimal effective dose to produce the observed effect. In addition, because the data in the registry are all anonymous, chart audits or other methods were not possible to independently validate continuous therapy, reasons for medication decisions, specific dosing, or the nature of drug-dosing decision making.
It is possible that the association between MMF maintenance therapy and better long-term renal function is the result of a direct effect of MMF on the progression of chronic allograft nephropathy, as indicated in animal studies (12) . Alternatively, we cannot exclude that the MMF group was not maintained with lower-maintenance CsA levels and therefore experienced reduced CNI related nephrotoxicity (11) (12) (13) . In addition, it is conceivable that better protection against early and late subclinical rejection by MMF may also mediate some of these long-term benefits (14) .
The design of this study was meant to be as rigorous as possible to avoid potential positive bias for the study drug. Potential sources of study bias included patients who lost their grafts, died or switched immunosuppression within the first year, and were excluded by design. Overall graft and patient survival during the first year were better in patients on MMF at discharge from the original transplant hospitalization compared with patients on MMF at discharge. In addition, it was hypothesized that excluding patients for switched therapy would result in a lower-risk population at 1 year in the MMF group. The analysis indicated that the opposite was true. Most of the drug switching occurred from AZA to MMF. As a result of excluding these patients, the AZA group at 1 year consisted of relatively low-risk patients in whom no switching was deemed necessary, likely stable posttransplant patients. Finally, although the AZA group as a whole was from a slightly earlier era, this was corrected for in the multivariate analysis. The positive association of MMF and improved renal function is significant given the specific bias of the study design against finding a beneficial effect of MMF.
CONCLUSION
This study demonstrated that long-term MMF therapy was associated with a decreased risk for worsening renal function, as measured by the slope of the reciprocal creatinine (20% decrease) and by reaching an SCr value greater than 1.6 mg/dL. In the multivariate analysis, MMF was a strong correlative protective factor against declining renal function. Similar benefits were also seen in patients treated with MMF continuously for 2 years after transplantation. Further study is indicated to confirm that continued MMF therapy is protective against long-term deterioration in renal function.
